Clinical Trial Update: CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of CAR20.19.22 T-cells in relapsed/refractory B-cell malignancies has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Chronic Lymphocytic Leukemia

Drugs mentioned

• CAR20.19.22 T-cells

Snippet

Sponsor: Medical College of Wisconsin | Conditions: B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Status: TERMINATED